Overview

Study of [212Pb]Pb-DOTAM-MAM279 in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

Status:
NOT_YET_RECRUITING

Trial end date:
2030-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[212Pb\]Pb-DOTAM-MAM279, in patients aged 18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3 positive tumors.

Phase:

PHASE1

Details

Lead Sponsor:

Molecular Partners AG

Collaborator:

Orano Med LLC